Eszopiclone
| Eszopiclone | |
|---|---|
 | |
| Molecular structure via molpic based on CDK |
| Physical properties [] | |
|---|---|
| Molecular mass | 388.8 g/mol [1] |
| Appearance | White to light-yellow crystalline solid [1] |
| Melting point | 202-203 [1] |
| Solubility | soluble in water [1] |
| Predicted LogP | 0.5 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C17H17ClN6O3 [1] |
| IUPAC name | [(7S)-6-(5-chloro-2-pyridinyl)-5-oxo-7H-pyrrolo[3,4-b]pyrazin-7-yl] 4-methylpiperazine-1-carboxylate [1] |
| SMILES | CN1CCN(CC1)C(=O)O[C@H]2C3=NC=CN=C3C(=O)N2C4=NC=C(C=C4)Cl [1] |
| InChI | InChI=1S/C17H17ClN6O3/c1-22-6-8-23(9-7-22)17(26)27-16-14-13(19-4-5-20-14)15(25)24(16)12-3-2-11(18)10-21-12/h2-5,10,16H,6-9H2,1H3/t16-/m0/s1 [1] |
| InChIKey | GBBSUAFBMRNDJC-INIZCTEOSA-N [1] |
| Pharmacokinetics[] | |
|---|---|
| Elimination half-life | 6 hours |
| Dosing[] |
|---|
| Sublingual [] | |
|---|---|
| Light | ≤ 6.8 mg(6x - 27.3%) |
| Common | 6.8 - 8.8 mg(5x - 22.7%) |
| Strong | 8.8 - 10 mg(7x - 31.8%) |
| Heavy | 10 - 14.7 mg(1x - 4.5%) |
| Extreme | 14.7 mg +(3x - 13.6%) |
| Oral [] | |
|---|---|
| Light | ≤ 13.2 mg(10x - 47.6%) |
| Common | 13.2 - 20 mg(5x - 23.8%) |
| Strong | 20 - 22.5 mg(1x - 4.8%) |
| Heavy | 22.5 - 30 mg(5x - 23.8%) |
| Extreme | 30 mg + |
Statistically derived dosages via DBI-IGS We do not take any responsibility for medical complications or loss of life sustained by following these dosages blindly. |
Eszopiclone (also known as Lunesta, Zopiclone, Estorra, Esopiclone, Eszopiclon, Eszopiclone civ, SEP-190, eszopiclona, (5S)-6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo(3,4-b)pyrazin-5-yl 4-methylpiperazine-1-carboxylate or [(7S)-6-(5-chloropyridin-2-yl)-5-oxo-7H-pyrrolo[3,4-b]pyrazin-7-yl] 4-methylpiperazine-1-carboxylate) is a
Chemistry
Stereochemistry []
Eszopiclone is a absolute mixture.
Druglikeness
Lipinski's rule of five
Eszopiclone matches Lipinski's rule of five.Pharmacology
ATC Classification
In the nervous system (N) eszopiclone acts as a benzodiazepine related drug (N05CF), eszopiclone (N05CF04), hypnotics and sedative (N05C) and psycholeptic (N05).[1]Legal status []
- Brazil: Eszopiclone is a B1 substance.[3]
- United States: Eszopiclone is a Schedule I under the "Controlled Substances Act (CSA)".
See also []
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 969472, Eszopiclone. Accessed June 12, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/969472
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Eszopiclone. UNII: UZX80K71OE. Global Substance Registration System. Accessed June 12, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/UZX80K71OE
Anvisa. RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. March 31, 2023. Accessed June 12, 2026. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992